Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.

Cancer research - 15 Apr 2024

Hu Bomiao, Wiesehöfer Marc, de Miguel Fernando J, Liu Zongzhi, Chan Lok-Hei, Choi Jungmin, Melnick Mary Ann, Arnal Estape Anna, Walther Zenta, Zhao Dejian, Lopez-Giraldez Francesc, Wurtz Anna, Cai Guoping, Fan Rong, Gettinger Scott, Xiao Andrew, Yan Qin, Homer Robert, Nguyen Don X, Politi Katerina

Abstract excerpt

The majority of EGFR mutant lung adenocarcinomas respond well to EGFR tyrosine kinase inhibitors (TKI). However, most of these responses are partial, with drug-tolerant residual disease remaining even at the time of maximal response. This residual disease can ultimately lead to relapses, which eventually develop in most patients. To investigate the cellular and molecular properties of residual tumor cells in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Basic Helix-Loop-Helix Transcription Factors

Share to Drug Resistance, Neoplasm

Share to Indoles

Share to Neoplasm Recurrence, Local

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 38359163
DOI: 10.1158/0008-5472.CAN-23-0438
PMCID: PMC11142404

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.PMID 38359163Read ↗

GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug ToleranceSemantic proximity Read ↗

Transcriptomic Analysis Reveals Early Alterations Associated with Intrinsic Resistance to Target Therapy in Lung Adenocarcinoma Cell LinesSemantic proximity Read ↗

Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinomaSemantic proximity Read ↗

Neuroendocrine-like/EMT dedifferentiation mediates resistance to EGFR inhibitors via the NRG1/HER3 axisSemantic proximity Read ↗

Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer.Semantic proximity Read ↗

Complementary modes of resistance to <i>EGFR</i> TKI in lung adenocarcinoma through MAPK activation and cellular plasticitySemantic proximity Read ↗

Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinomaSemantic proximity Read ↗

Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung CancerSemantic proximity Read ↗

Elevated Expression of <i>MALAT1</i> Contributes to the Survival of Drug-Tolerant Persister Cells Following Targeted Therapy in Lung AdenocarcinomaSemantic proximity Read ↗

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.Semantic proximity Read ↗

Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.